Abstract. The purpose of the present study was to screen potential pathogenic biomarkers of clear cell renal cell carcinoma (ccRCC) via microarray analysis. The mRNA and microRNA (miRNA) expression profiles of GSE96574 and GSE71302 were downloaded from the Gene Expression Omnibus (GEO) database, as well as the methylation profile of GSE61441. A total of 5 ccRCC tissue samples and 5 normal kidney tissue samples were contained in each profile of GSE96574 and GSE71302, and 46 ccRCC tissue samples and 46 normal kidney tissue samples were involved in GSE61441. The differentially expressed genes (DEGs) and the differentially expressed miRNAs (DEMs) were obtained via limma package in ccRCC tissues compared with normal kidney tissues. The Two Sample t-test and the Beta distribution test were used to identify the differentially methylated sites (DMSs). The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used to perform the Gene Ontology (GO) term and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses of the DEGs. The targets of the DEMs were screened with the miRWalk database, and the further combination analyses of DEGs, DEMs and DMSs were conducted. Additionally, reverse transcription PCR (RT-PCR) and methylation-specific PCR (MS-PCR) were performed to detect the mRNA level and methylation status of HAPLN1. The mRNA levels of hsa-miR-204 and hsa-miR-218 were tested by RT-PCR. A total of 2,172 DEGs, 202 DEMs and 2,172 DMSs were identified in RCC samples compared with normal samples. The DEGs were enriched in 1,015 GO terms and 69 KEGG pathways. A total of 10,601 miRNA-gene pairs were identified in at least 5 algorithms of the miRWalk database. A total of 143 overlaps were identified between the DEGs and the differentially methylated genes. Furthermore, the DEGs were involved in 851 miRNA-gene pairs, including 127 pairs in which the target genes were negatively associated with their corresponding DEMs and DMSs. HAPLN1 was lowly expressed and highly methylated in ccRCC tissues, while hsa-miR-204 and hsa-miR-218 were highly expressed. The results of the present study indicated that HAPLN1, hsa-miR-204 and hsa-miR-218 may be involved in the pathogenesis of ccRCC.
Introduction
Renal cell carcinoma (RCC) is the most common type of kidney cancer responsible for 90-95% of all cases, and accounting for ~3% of adult malignancies (1) . Clear cell RCC (ccRCC) is the most aggressive RCC subtype and constitutes 70-80% of all RCC cases with the highest rates of local invasion, metastasis and mortality (2) . RCC is usually asymptomatic in the early stages and, as the disease progresses, signs include hematuria, flank pain, abdominal masses and loin pain (3) . An unhealthy lifestyle is a major cause of RCC, and it has been reported that smoking, obesity and hypertension have been estimated to cause ~50% of all cases (4) . Additionally, hereditary factors have an impact on individual susceptibility to RCC (5) . Other genetically-linked conditions also increase the risk of developing RCC, including hereditary papillary renal carcinoma, hereditary leiomyomatosis, hyperparathyroidism-jaw tumor syndrome, familial papillary thyroid carcinoma and sickle cell disease. The pathogenesis of RCC is extremely complex and is yet to be elucidated. Notably, an increasing number of biomarkers have been found to be involved in the pathogenesis of RCC. Matsuura et al (6) proved that the downregulation of SAV1 and the consequent YAP1 activation were involved in the pathogenesis of high-grade ccRCC. Furthermore, bioinformatics analyses demonstrated that microRNAs (miRNAs) were dysregulated in ccRCC and may contribute to kidney cancer pathogenesis by targeting more than 1 key molecule (7) . A larger number of miRNAs are associated with key pathogenesis mechanisms of hypoxia and epithelial-to-mesenchymal transition, including miR-200, miR-210, miR-155, miR-8a, miR-424, miR-381, miR-34a, miR-17-5p and miR-224 (8) . In addition, promoter region methylation and transcriptional silencing are major mechanisms of tumor suppressor genes Identification of potential pathogenic biomarkers in clear cell renal cell carcinoma ZENGZENG WANG 1, 2 , ZHIHONG ZHANG 1 , CHANGWEN ZHANG 1 and YONG XU in RCC (9) . Ricketts et al (10) reported that certain tumor suppressor genes were methylated in RCC tumor tissue (e.g., SLC34A2 was specifically methylated in 63% of RCC cases, OVOL1 in 40%, DLEC1 in 20%, TMPRSS2 in 26%, SST in 31% and BMP4 in 35%). Therefore, the methylation analysis is an attractive strategy for investigating novel genes in the pathogenesis of RCC. In the present study article, an mRNA expression profile, a miRNA expression profile and a methylation profile of ccRCC were synthetically analyzed in order to screen potential pathogenic biomarkers via microarray analysis.
Materials and methods
Microarray data. The microarray datasets of GSE96574, GSE71302 (11) and GSE61441 (12) were downloaded from the Gene Expression Omnibus (GEO) database (www.ncbi.nlm. nih.gov/geo/). GSE96574, which was an mRNA expression profile with 5 ccRCC tissues and 5 normal kidney tissues, was detected with the platform of Agilent-067406 CBC lncRNA + mRNA microarray V4.0; GSE71302, an miRNA expression profile with 5 ccRCC tissues and 5 normal kidney tissues, was detected with the platform of Agilent-021827 Human miRNA Microarray V3; GSE61441, a methylation profile with 46 ccRCC tissues and 46 normal kidney tissues, was detected with the platform of Illumina HumanMethylation450 BeadChip.
Data processing and differential analysis. For the profiles of GSE96574, GSE71302 and GSE61441, the raw data were obtained and normalized using the preprocess core function package V3.5 (http:// www .bioconductor .org /packages/release/ bioc /html /preprocessCore .html) (13) . Subsequently, the differentially expressed genes (DEGs) and differentially expressed miRNAs (DEMs) were identified in ccRCC samples compared with normal kidney samples with the limma V3.18.13 software package (http://www.bioconductor.org/packages/ 2.13/bioc/html/limma.html). P<0.05 and |log 2 (fold-change)|>1 were used as threshold criteria. The two sample t-test and the β distribution test were used to identify the differentially methylated sites (DMSs), and DMSs were identified with P<0.05 and |Δβ|>0.2. Furthermore, the genes in which the DMSs were located were labeled using the annotation files of the methylation chip platform. The tumor tissues and adjacent non-cancerous tissues were collected with surgical resection. Written informed consent was obtained when the patients were accepted by the Second Hospital of Tianjin Medical University. All procedures were performed in accordance with the ethical standards of the institutional and/or national research committee. The total RNA was extracted using TRIzol (Invitrogen; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Reverse transcription PCR (RT-PCR) and methylation-specific PCR (MS-PCR) were performed to detect the methylation status of HAPLN1. The mRNA levels of HAPLN1, hsa-miR-204 and hsa-miR-218 were tested by RT-PCR. RNA was reverse transcribed using the PrimeScript ® 1st Strand cDNA Synthesis kit (Takara Biotechnology Co., Ltd., Dalian, China) with the following temperature protocol: 30˚C for 10 min, 42˚C for 60 min and 95˚C for 5 min. The SYBR ® Premix Ex Taq™ kit (Takara Biotechnology Co., Ltd.) and the Applied Biosystems™ QuantStudio™ 5 Real-Time PCR System (Applied Biosystems; Thermo Fisher Scientific, Inc.) were used to conduct PCR, according to the manufacturer's protocols. DNA methylation modification was performed using an EZ-DNA Methylation-Gold kit TM (Zymo Research Corp., Irvine, CA, USA), according to the manufacturer's protocols. All the primers were designed and synthesized by Takara Biotechnology Co., Ltd. The MSP primers of HAPLN1 were as follows: Forward, Statistical analysis. SPSS version 17.0 (SPSS Inc., Chicago, IL, USA) was used for all statistical analyses, and data are presented as the mean ± standard deviation. T test was used to compare the two groups and P<0.05 was considered to indicate a statistically significant difference. Tables I, II and III, respectively. The location distribution of DMSs is presented in Fig. 1 , and they were primarily located in the gene coding region (31%) and the intergenic gene region (22%).
Results

DEGs, DEMs and
Enriched GO terms and KEGG pathways. The DEGs were enriched in 1,015 GO terms and 69 KEGG pathways. The top 10 significantly enriched GO terms and KEGG pathways are presented in Tables IV and V, respectively.
Targets of DEMs.
The target genes of DEMs were identified in at least 5 algorithms of the miRWalk database and therefore, 10,601 miRNA-gene pairs were obtained. The locations of the target genes and the regulation trends of the miRNA-gene pairs are presented in Fig. 2 . More targets were located in the 3'-UTR, fewer in the 5'-UTR and coding domain sequence (CDS) and the majority of miRNA-gene pairs were negatively regulated.
Combination of DEGs, DEMs and DMSs. In total, 143 DEGs involved in DMSs were identified in ccRCC samples compared with normal kidney samples. The gene expression level and DNA methylation level of 45 of these genes exhibited inverse associations (Fig. 3) . A total of 851 miRNA-gene pairs were simultaneously involved in DEGs, DEMs and DMS-located genes. Among them, there were 127 miRNA-gene pairs, the genes of which were negatively associated with corresponding DEMs and DMSs. Furthermore, 32 of these miRNA-gene pairs, of which the targeted genes had well-defined genetic locations, are presented in Table VI . The 32 miRNA-gene pairs were composed of 15 genes and 14 miRNAs. HAPLN1 had the most significant differences in expression and was regulated by hsa-miR-204 and hsa-miR-218. Results of the verification are presented in Table VII ; HAPLN1 had a lower expression level and a significantly higher methylation level was significantly higher in ccRCC tissues than in adjacent non-cancerous tissues (P<0.0001). 
Discussion
Genetic variations are associated with the occurrence and development of RCC. miRNAs regulate gene expression and serve an important role in the development of cancer. The methylation status of certain genes is associated with cancer development and metastatic recurrence in ccRCC. In the present study, the mRNA and miRNA expression profiles, as well as the methylation profiles, were analyzed. A total of 2,172 DEGs, 202 DEMs and 2,172 DMSs were identified in ccRCC samples compared with normal kidney samples. The DEGs were enriched in 1,015 GO terms, and the majority of them were associated with the plasma membrane, extracellular exosome and material transport, including the plasma membrane part, extracellular exosome and ion transport (Table IV) . Plasma membrane part was the most significant GO term for the DEGs. Plasma membrane part is a cellular component term, which participates in regulating DNA methylation and the mechanism of glioma (17) (18) (19) . Human plasma membrane-associated sialidase (NEU3), an important cellular component of cell membrane part, serves crucial roles in the regulation of KEGG, Kyoto Encyclopedia of Genes and Genomes. Figure 1 . The location distribution of DMSs in genes. The body indicates the gene coding region. TSS200, the 200 bp upstream of the transcription start site; TSS1500, the 1,500 bp upstream of the transcription start site; 5'-UTR, the 5'-untranslated region; 1stExon, the first exon region; 3'-UTR, the 3'-untranslated region; IGS, intergenic gene region; DMSs, the differentially methylated sites.
cell surface functions. Ueno et al (20) reported that NEU3 was upregulated in RCC and promoted interleukin-6-induced apoptosis suppression and cell motility. Tringali et al (21) demonstrated a crucial role of NEU3 in RCC malignancy by acting as a key regulator of the β1 integrin-recycling pathway and FAK/Akt signaling. Therefore, the cellular component term of plasma membrane part was associated with the progression of RCC. Furthermore, the DEGs were enriched in 69 KEGG pathways, including graft-versus-host disease, staphylococcus aureus infection, type I diabetes mellitus and rheumatoid arthritis. Graft-versus-host disease (GvHD) was the most significant pathway. GvHD is a medical complication following the receipt of transplanted tissue from a genetically different person. It is commonly associated with stem cell transplant (bone marrow transplant), but the term also applies to other forms of tissue graft. A previous study revealed a reduced rate of GvHD during cyclophosphamide-using non-myeloablative cell therapy against renal cancer (22) . Another study indicated that the graft vs. tumor reactivity following allogeneic stem cell transplantation may be unavoidably associated with GvHD in patients with RCC (23). Additionally, Massenkeil et al (24) reported that non-myeloablative stem cell transplantation in metastatic renal cell carcinoma delayed GvHD. In the present study, we hypothesized that GvHD may serve certain roles in the pathogenesis of RCC and that further functional studies were required. Following combination analysis of DEGs, DEMs and DMSs, HAPLN1 was one of the DEGs that was negatively regulated by their corresponding targeted DEMs and DMSs, and it had well-defined genetic locations. Furthermore, HAPLN1 exhibited the most pronounced differences in expression, and was negatively regulated by hsa-miR-204 and hsa-miR-218. Table VI indicates that hsa-miR-204 and hsa-miR-218 targeted the 3'-UTR of HAPLN1. It is well known that miRNAs block the transcription of their target genes when they target the 3'-UTR (25) . In the present study, the expression of HAPLN1 was negatively associated with the expression of hsa-miR-204 and hsa-miR-218. Additionally, the methylation site of HAPLN1 is located in the transcriptional start site 1,500 bp (TSS1500) region. In this region, gene methylation may lead to deletion or downregulation of gene expression. In the present study, the expression of HAPLN1 was negatively associated with the methylation level. Furthermore, HAPLN1 and hsa-miR-204 were the most significantly different gene and DEM, respectively (Table VI) . HAPLN1 is a protein that in humans is encoded by the HAPLN1 gene. HAPLN1 is an extracellular matrix component serving an important role in heart development, and is associated with cerebral creatine deficiency syndrome and fracture. It was reported that overexpression of HAPLN1 and its SP-IgV domain increased the tumorigenic properties of mesothelioma (26) . Yau et al (27) identified HAPLN1 as a novel prognostic gene candidate to predict the outcome of breast cancer. Mebarki et al (28) proved that HAPLN1 reflected a signaling network leading to stemness, mesenchymal commitment and progression in hepatocellular carcinoma. The present study, revealed that HAPLN1 had a low expression level and a high methylation level in ccRCC tissues (Table VII) , which may be involved in the occurrence of ccRCC. Hsa-miR-204 was identified to be highly expressed in lymphocytic leukemia, and it was differentially expressed during the progression of recurrence in hepatocellular carcinoma and gastric cancer (29) (30) (31) . Hsa-miR-218 was reported to serve an important role in the proliferation and metastasis of colon carcinoma (32) . Additionally, hsa-miR-218 may inhibit the multidrug resistance of gastric cancer cells (33) . In the present study, hsa-miR-204 and hsa-miR-218 were proven to be highly expressed in ccRCC tissues, and may serve certain roles in the pathogenesis of RCC by targeting HAPLN1.
In conclusion, the present study identified certain biomarkers of RCC by combination analysis of a mRNA expression profile, a miRNA expression profile and a methylation profile, including HAPLN1, hsa-miR-204 and hsa-miR-218. Additionally, the cellular component of plasma membrane part and the pathway of GvHD may be involved in 
